Table 4 Statistical significance of hepatic lipid profile and malondialdehyde concentration in hypercholesterolemic rats treated with bezafibrate, quinazolinone and halogenated derivatives, compared to control group

Total lipids

Mean ± SD

75.30 ± 7.86^a

60.16 ± 4.18^b

52.11 ± 13.07^b

56.47 ± 9.50^b

56.32 ± 12.94^b

Range

(68.24–88.24)

(54.90–66.27)

(36.86–74.90)

(41.57–68.24)

(41.57–76.08)

Change%

-

-20.11

-30.80

-25.01

-25.21

Triacylglycerol

Mean ± SD

10.55 ± 2.66^a

6.01 ± 1.39^b

9.83 ± 2.17^a

7.85 ± 2.75^b

8.05 ± 1.35^b

Range

(7.09–14.91)

(4.09–7.83)

(7.30–13.91)

(4.39–11.74)

(6.65–10.50)

Change%

-

-43.03

-6.82

-25.59

-23.70

Total cholesterol

Mean ± SD

25.18 ± 2.77^ab

25.64 ± 1.48^a

22.71 ± 2.13^b

22.80 ± 2.01^b

22.83 ± 2.13^b

Range

(20.58–28.46)

(23.98–28.32)

(19.11–25.85)

(20.00–25.39)

(19.12–25.61)

Change%

-

1.83

-9.81

-9.45

-9.33

Free cholesterol

Mean ± SD

5.80 ± 1.70^a

5.23 ± 1.32^a

12.78 ± 2.46^b

9.64 ± 1.30^c

9.47 ± 1.50^c

Range

(3.37–8.13)

(3.85–6.83)

(9.52–17.33)

(7.68–11.45)

(7.22–11.51)

Change%

-

-9.83

120.34

66.21

63.28

Ester cholesterol

Mean ± SD

19.38 ± 1.67^a

20.42 ± 1.00^a

9.56 ± 1.56^b

13.16 ± 1.30^c

13.36 ± 1.20^c

Range

(16.99–21.76)

(19.35–22.47)

(7.57–11.43)

(11.11–14.51)

(11.67–15.56)

Change%

-

5.37

-50.67

-32.09

-31.06

MDA(nmol/g)

Mean ± SD

131.31 ± 15.10^a

229.73 ± 4.76^b

214.18 ± 23.85^b

196.75 ± 26.44^b

211.16 ± 14.54^b

Range

(113.33–155.42)

(223.53–238.43)

(172.42–246.01)

(161.57–229.28)

(188.37–230.33)

Change%

-

74.95

63.11

49.84

60.81